Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 13, 2026HaematologicaOpen Access

Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1

View Full Paper
Ask AI
Bookmark
Share

Authors

DVDeeksha VishwamitraJohnson & Johnson (United States)SSSheri SkergetJohnson & Johnson (United States)DCDiana Cortés‐SelvaJohnson & Johnson (United States)

Discussion

Loading...

Member takes

Implication

Longitudinal trial correlates immune profiles with teclistamab response in multiple myeloma, suggesting strategies for improved outcomes.

Key Points

  • This research aims to analyze the immune mechanisms associated with response, resistance, and relapse to teclistamab in multiple myeloma patients.
  • Longitudinal analysis of immune profiles in patients receiving teclistamab treatment from MajesTEC-1 (ClinicalTrials.gov NCT03145181/NCT04557098).
  • Collection of bone marrow and peripheral blood samples at baseline, during treatment, and at disease progression.
  • Assessment of T-cell activation levels and BCMA antigen expression in correlation with clinical outcomes.
  • Responders to teclistamab showed increased T-cell activation and margination compared to nonresponders.
  • Nonresponders displayed sustained checkpoint marker expression and higher regulatory T cells, indicating persistent immune suppression.
  • At relapse, higher proportions of dysfunctional T cells and reduced BCMA receptor density on tumor plasma cells were observed.

Cite This Study

Vishwamitra et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf6d7faef96ed7f05882ehttps://doi.org/10.3324/haematol.2026.300526
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study2024 · 65 citations
  2. 2The resistec study: Dissecting immune correlates of resistance and response to teclistamab in real-world multiple myeloma2025
  3. 3Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies2024 · 67 citations
  4. 4Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma.2024 · 92 citations
  5. 5Real-world outcomes of teclistamab for the treatment of relapsed/refractory multiple myeloma at UC San Diego Health: A single-institution experience.2024 · 5 citations